CD8A and cancer: Since affinity of peptides to MHC I has withstood the test of time as a key criterion for predicting immunogenicity, this has been applied to the discovery of cancer neoepitopes as well, and a number of high affinity neoepitopes that elicit tumor rejection as well as CD8 T cell responses measurable in vitro, have been identified4–6.